SCHEMBL119179

SCHEMBL119179

CNCCc1c[nH]cn1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL614543 0.98 TAAR1 (0.47)
Bromide SCHEMBL1423332 0.98 HRH3 (0.44)
SCHEMBL9500613 0.88 NOS3 (0.41)
SCHEMBL14886894 0.86 L3MBTL1 (0.40)
Fumaric Acid SCHEMBL27205408 0.84 ALDH1A1 (0.37)
Trifluoroacetic Acid SCHEMBL19816089 0.84 LMNA (0.36)
SCHEMBL31364603 0.83 ALDH1A1 (0.31)
SCHEMBL31364605 0.83 ALDH1A1 (0.31)
SCHEMBL2893056 0.80 HRH4 (0.38)
SCHEMBL11289554 0.79

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1543 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4679087-A1 BIOMARKER AND USE THEREOF MEIJI CO., LTD (JP) 2026-01-14 EP claimed
CN-118725014-A Mitochondrial targeting peptides 隐形生物治疗公司 2024-10-01 CN claimed
CN-118702767-A Mitochondrial targeting peptides 隐形生物治疗公司 2024-09-27 CN claimed
CN-118702766-A Mitochondrial targeting peptides 隐形生物治疗公司 2024-09-27 CN claimed
WO-2024190663-A1 BIOMARKER AND USE THEREOF 株式会社明治 2024-09-19 WO claimed
US-20240277668-A1 HISTAMINE RECEPTOR AGONISTS FOR CANCER THERAPY IN CANCER PATIENTS UNRESPONSIVE TO CANCER IMMUNOTHERAPY AND WITH ELEVATED MYELOID DERIVED SUPPRESSOR CELLS TSP THERAPEUTICS INC. 2024-08-22 US claimed
US-20240269123-A1 MUSCLE REGENERATION PROMOTER SATO PHARMACEUTICAL CO., LTD. (JP) 2024-08-15 US claimed
US-20240219399-A1 DIFFERENTIAL DIAGNOSIS OF HISTAMINE INTOLERANCE SYNDROME IMMUNDIAGNOSTIK AG (DE) 2024-07-04 US claimed
EP-4376835-A1 HISTAMINE RECEPTOR AGONISTS FOR CANCER THERAPY IN CANCER PATIENTS UNRESPONSIVE TO CANCER IMMUNOTHERAPY AND WITH ELEVATED MYELOID DERIVED SUPPRESSOR CELLS TSP Therapeutics Inc. (US) 2024-06-05 EP claimed
US-20240165082-A1 ORALLY ADMINISTERED COMPOSITIONS FOR CANCER TREATMENT TSP THERAPEUTICS INC. 2024-05-23 US claimed
EP-1200074-A2 USE OF DIPHENYLIODONIUM FOR THE ACTIVATION AND PROTECTION OF CYTOTOXIC LYMPHOCYTES Maxim Pharmaceuticals, Inc. (US) 2002-05-02 EP claimed
WO-2001006756-A2 USE OF DIPHENYLIODONIUM FOR THE ACTIVATION AND PROTECTION OF CYTOTOXIC LYMPHOCYTES MAXIM PHARMACEUTICALS, INC. (US) 2001-01-25 WO claimed
US-6028095-A Treatment of inflammatory bowel disease using histamine H3 -receptor agonists WARNER-LAMBERT COMPANY (US) 2000-02-22 US claimed
EP-0748217-A1 COMPOSITIONS COMPRISING A MAST CELL DEGRANULATION-BLOCKING AGENT FOR TREATMENT OF ENDOGENOUS, PAINFUL GASTROINTESTINAL CONDITIONS OF NON-INFLAMMATORY, NON-ULCERATIVE ORIGIN KOS PHARMACEUTICALS, INC. (US) 1996-12-18 EP claimed
WO-1995021611-A2 COMPOSITIONS COMPRISING A MAST CELL DEGRANULATION-BLOCKING AGENT FOR TREATMENT OF ENDOGENOUS, PAINFUL GASTROINTESTINAL CONDITIONS OF NON-INFLAMMATORY, NON-ULCERATIVE ORIGIN KOS PHARMACEUTICALS, INC. (US) 1995-08-17 WO claimed
EP-0612525-A1 Transdermal treatment with mast cell degranulating agents for drug-induced hypersensitivity BRISTOL-MYERS SQUIBB COMPANY (US) 1994-08-31 EP claimed
EP-0214058-B1 PHARMACEUTICAL COMPOSITION CONTAINING HISTAMINE DERIVATIVES INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 1992-05-06 EP claimed
EP-0214058-A2 Pharmaceutical composition containing histamine derivatives INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 1987-03-11 EP claimed
EP-0209586-A1 ANTI-HISTAMINE ANTIBODY PREPARATION WITH SPECIFICITY FOR A 4-(2-AMINOETHYL)IMIDAZOLYL GROUP ATTACHED DIRECTLY TO AN ALKYLENE CHAIN AND IMMUNOASSAY METHOD EMPLOYING THE PREPARATION. PHARMACIA AB (SE) 1987-01-28 EP claimed
WO-1986004420-A1 ANTIBODY PREPARATION WITH SPECIFICITY FOR ALIPHATICALLY BOUND 4-(2-AMINOETHYL)IMIDAZOLYL GROUP, MANUFACTURE AND USE OF THE ANTIBODY PREPARATION PHARMACIA AB (SE) 1986-07-31 WO claimed